Enfortumab Vedotin in Patients With Advanced Small Bowel Adenocarcinoma Refractory or Intolerant to Platinum-based Combination Therapy

NCT07347314 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

27

Enrollment

OTHER_GOV

Sponsor class

Conditions

Advanced Small Bowel Adenocarcinoma

Interventions

DRUG: Enfortumab vedotin

Sponsor

National Cancer Center, Japan

Collaborators

[object Object]